The research goals of the Department of Pediatric Oncology are to promote basic laboratory research, translational investigation, and clinical studies to better understand and treat childhood cancers. Under the leadership of Scott A. Armstrong, MD, PhD,
research across the continuum from laboratory research to clinical trials is contributing to the improvement of care for children with cancer with a particular emphasis on the development of new therapeutic approaches. In this setting, the Department
also provides an exceptional training environment for basic and clinical researchers.
Through our combined program with Boston Children's Hospital — Dana-Farber/Boston Children's Cancer and Blood Disorders Center — the Department is developing unique pediatric clinical trials to improve the treatment and care of children with cancer. The
Department's clinical trials portfolio includes investigator-initiated, cooperative group, and company-sponsored trials for a variety of cancers at different stages of progression.
Director of Clinical Genomics, Katherine Janeway, MD
- Using tumor-profiling techniques to genetically define patients' tumors and match them with targeted therapies
- Linking basic discoveries emanating from departmental laboratory research and the Center for Pediatric Cancer Therapeutics to genetically-matched pediatric patients
Center for Pediatric Cancer Therapeutics
Co-Directors Scott Armstrong, MD, PhD, and Kimberly Stegmaier, MD
- Working closely with colleagues in the Dana-Farber Chemical Biology Program to identify new small molecules that target proteins relevant for childhood cancers
- Developing experimental and computational tools to dissect the genetic and epigenetic determinants of pediatric cancers
- Validating new therapeutic targets and drugs through in vivo pediatric models of disease, including patient-derived xenografts
- Providing the preclinical datasets required for translation into the clinic
Basic and Translational Research
The Department's basic and translational research focus spans hematological malignancies, solid tumors, neuro-oncology, experimental therapeutics, and cancer biology. There are approximately 15 independent research laboratories conducting research in the Department.